Nagano, Japan

Masahiro Yanagiya

This inventor holds 1 USPTO granted patent. Top assignee: Kotobuki Pharmaceutical Co Ltd. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Yanagiya. Retrieved from https://idiyas.com/inventor/masahiro-yanagiya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Yanagiya: Innovator in Synthetic Compounds

Introduction

Masahiro Yanagiya is a notable inventor based in Nagano, Japan. He has made significant contributions to the field of synthetic compounds, particularly in the development of innovative solutions for medical applications. His work focuses on creating compounds that can induce immune responses for critical health issues such as cancer and HIV.

Latest Patents

Yanagiya holds a patent for "Non-mucin type synthetic compounds or its carrier conjugated compounds." The purpose of this invention is to prepare non-mucin type synthetic compounds that are stable against enzymes and possess the ability to induce specific immune responses. This advancement is particularly relevant for combating diseases like cancer and HIV. He has 1 patent to his name.

Career Highlights

Masahiro Yanagiya is associated with Kotobuki Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work is characterized by a commitment to enhancing the efficacy of therapeutic compounds.

Collaborations

Yanagiya has collaborated with notable colleagues, including Hiroshi Tomiyama and Yasufumi Ohkura. Their combined expertise has furthered the development of groundbreaking solutions in the field of synthetic compounds.

Conclusion

Masahiro Yanagiya's contributions to synthetic compounds represent a significant advancement in medical science. His innovative work continues to pave the way for new treatments and therapies that can improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…